PTAB Urged To Review CRISPR Gene-Editing Patent
An agriculture biotech company on Tuesday urged the Patent Trial and Appeal Board to invalidate a patent related to gene-editing technology CRISPR-Cas9 that is held by the Massachusetts-based Broad Institute, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article